Broadcast Date: 
  • Time: 

Novel therapeutic modalities such as bispecific antibodies (BsAbs) that simultaneously target two antigens are demonstrating promising clinical results in oncology with benefits that include enhanced specificity, reduced side effects, and increased efficacy. Despite the challenges in developing BsAbs, progress in protein/antibody engineering has resulted in an increase in BsAbs and their preclinical assessment.

In this webinar, you’ll learn about: 

  • How recent advances in preclinical tools, translation research, and the use of omics data are narrowing the gap between the lab and patient.    
  • A Novel BsAb targeting both PD1 & CD47, and challenges and opportunities for IO strategy to target and modulate adaptive and innate immune system.
  • Evidence-based identification of potential clinical indications.

Register today to gain invaluable insights on the development of BsAbs from our industry experts.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Rajendra Kumari, PhD
Executive Director, Integrated Solutions
Crown Bioscience
Henry Li
Henry Li, PhD
Chief Executive Officer and Chief Scientific Officer
Hanx Biopharmaceuticals


Comments are closed.